This site is intended for healthcare professionals. If you are a patient or caregiver, please contact your physician to discuss clinical trial eligibility.
Preclinical Development and Lead Optimization Exploring FGFR
The fibroblast growth factor receptor (FGFR) family of tyrosine kinases consists of 4 isoforms (FGFR1, FGFR2, FGFR3, FGFR4), which are structurally similar to each other but play very different roles in human cancer.
Fusions, point mutations, and gene amplifications in individual isoforms of the FGFR family have been associated with distinct cancer types in patients. While tyrosine kinase inhibitors (TKIs) with anti-FGFR activity have produced clinical responses in patients whose tumors harbor FGFR alterations, currently available FGFR TKIs inhibit multiple other kinases, including multiple isoforms of FGFR.1 As a result, dose-limiting toxicities have been observed frequently in patients.1 In developing our candidate compounds, we believe that sparing FGFR1 may be an important attribute for maximizing therapeutic inhibition of FGFR2 and FGFR3 in patients whose tumors harbor genetic abnormalities in those 2 genes.
- Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318-322.